Bambusa Therapeutics director reports 153,908-share option

Q: How many shares are covered by Howard Liang's BBTX stock option, and at what exercise price?

The option covers 153,908 common shares and has an exercise price of $8.04 per share.

Subject to continued service as a director through each applicable vesting date, one thirty-sixth (1/36th) of the option shares vests monthly following July 1, 2026.

Accepted by SEC EDGAR 10/29/2026 - 04:31 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Howard Liang, a director of Bambusa Therapeutics, Inc. (BBTX), reported a directly held stock option covering 153,908 common shares at an exercise price of $8.04 per share, with an expiration date of July 9, 2036. The reported security is the option itself, with Common Stock listed as its underlying security, rather than a transaction in the underlying shares.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Liang Howard

Role Director

Type	Security	Shares	Price	Value
Holding	Stock Option (right to buy) ^F1	--	--	--

Holdings: Stock Option (right to buy) — 153,908 contracts (Direct)

Footnotes (1)

F1. Subject to the Reporting Person continuing to be a Director (as defined in the Issuer's 2024 Stock Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 1, 2026.

Key Figures

Underlying option shares: 153,908 common shares Exercise price: $8.04 per share Option expiration: July 9, 2036 +1 more

4 metrics

Underlying option shares 153,908 common shares Shares covered by Howard Liang's directly held stock option.

Exercise price $8.04 per share Price to buy the underlying Common Stock under the option.

Option expiration July 9, 2036 Expiration date of the stock option.

Monthly vesting 1/36th of option shares Each month following July 1, 2026, subject to continued service as a director through each applicable vesting date.

Key Terms

Stock Option (right to buy), Vesting Commencement Date, 2024 Stock Plan

3 terms

Stock Option (right to buy) financial

"Stock Option (right to buy)"

Vesting Commencement Date financial

""Vesting Commencement Date" shall mean"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

2024 Stock Plan financial

"as defined in the Issuer's 2024 Stock Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares are covered by Howard Liang's BBTX stock option, and at what exercise price?

The option covers 153,908 common shares and has an exercise price of $8.04 per share.

How does Howard Liang's BBTX option vest?

Subject to Howard Liang continuing to be a director through each applicable date, one thirty-sixth (1/36th) of the option shares vests each month following the July 1, 2026 Vesting Commencement Date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Liang Howard

(Last)

(First)

(Middle)

C/O BAMBUSA THERAPEUTICS, INC.

22 BOSTON WHARF ROAD, FLOOR 7

(Street)

BOSTON

MASSACHUSETTS

02210

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/29/2026

3. Issuer Name and Ticker or Trading Symbol
Bambusa Therapeutics, Inc. [ BBTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	07/09/2036	Common Stock	153,908	$8.04	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Director (as defined in the Issuer's 2024 Stock Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 1, 2026.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jonathan I. Lieber, as attorney-in-fact	10/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR